Core Viewpoint - San Yuan Gene reported a slight increase in revenue for the first half of the year, while facing increased costs due to depreciation, operational maintenance, and interest expenses related to new facility construction and R&D investments [2] Group 1: Financial Performance - The company achieved operating revenue of 118 million yuan, representing a year-on-year increase [2] - The net profit attributable to shareholders decreased year-on-year, but the second quarter net profit reached 5.7851 million yuan, indicating a significant recovery from the first quarter [2] - R&D expenses for the first half amounted to 12.9358 million yuan, accounting for 10.93% of operating revenue, with a year-on-year growth of 103.31% [2] Group 2: R&D Focus - The company is focusing on the development of a new PEG-integrated interferon mutant for the treatment of chronic hepatitis B, which is expected to significantly improve clinical cure rates [3] - San Yuan Gene is utilizing advanced genome-wide detection technology to identify suitable patient populations for the new interferon treatment, positioning itself as a leader in precision medicine for hepatitis B [3] - The company has completed the enrollment of 940 subjects for genome-wide detection clinical studies, with 149 new enrollments during the reporting period [3] Group 3: Collagen Protein Development - San Yuan Gene has made significant progress in the development of recombinant human collagen products, achieving the world's first efficient production of recombinant human type II and III collagen based on mammalian cell expression [4] - The company plans to increase R&D investment in collagen-related cosmetic and medical device products, aiming for regulatory approval and market launch in phases [4] - The focus on accelerating technology transfer and deepening industry collaboration is intended to enhance the company's core competitiveness in the collagen field [4]